# Braveheart Bio, Inc. Common Stock (BRVE)

> Braveheart Bio, Inc. Common Stock (BRVE) trades at $18.00 (-4.15%) as of 4:29:23 PM EST on Nov 18, 2026, -8.58% over the past month. Market cap is $1.67B, with 19.6 days to cover in short interest.

Canonical: https://massive.com/quote/brve
Data as of: 2026-11-18T21:29:23.671Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$18.00** -0.78 (-4.15%)
As of 4:29:23 PM EST on Nov 18, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Braveheart Bio, Inc. Common Stock (BRVE) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.33% |
| 1W | -11.34% |
| 1M | -8.58% |
| YTD | -37.82% |
| 1Y | -37.82% |
| 52-wk range | $16.70 – $32.00 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for BRVE: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $17.94 – $19.46 |
| Open | $18.75 |
| Prev close | $18.78 |
| Volume | 706.91K |
| Market cap | $1.67B |
| Shares out | 90.04M |

## Insider trading

[Braveheart Bio, Inc. Common Stock (BRVE) insider trading](https://massive.com/quote/brve/insider-trading.md): open-market Form 4 buys and sells by Braveheart Bio, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Braveheart Bio, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 10, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 10, 2026, Braveheart Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.”
- Nov 6, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On November 6, 2026, Braveheart Bio, Inc. issued a press release titled “Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026.””
- Sep 8, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On September 8, 2026, Braveheart Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter ended June 30, 2026.”
- Aug 7, 2026 · Charter amendment
  “The Company filed its second amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on August 7, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.”

## BRVE short interest

How heavily BRVE is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 19.6 |
| Short interest | 5.15M |
| Avg volume | 262.57K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## BRVE news

The latest news and headlines about Braveheart Bio, Inc. Common Stock (BRVE).

- [Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?](https://www.fool.com/coverage/filings/2026/08/10/braveheart-bio-chairman-chris-viehbacher-buys-usd1-5m-shares-at-ipo-what-does-this-mean-for-investors/?source=iedfolrf0000001) · The Motley Fool · Aug 10, 2026 · positive sentiment

## About Braveheart Bio, Inc. Common Stock

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO | $18.00 on Aug 6, 2026 |

[Braveheart Bio IPO page](https://massive.com/quote/brve/ipo.md)

[Company website](https://www.braveheart.bio)

## FAQ

### What is the Braveheart Bio, Inc. Common Stock (BRVE) stock price today?

Braveheart Bio, Inc. Common Stock (BRVE) is trading at $18.00 (-4.15% on the day) as of 4:29:23 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Braveheart Bio, Inc. Common Stock?

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases.

### What is the short interest in BRVE?

As of Oct 30, 2026, BRVE has 5.15M shares short and 19.6 days to cover.

### What exchange is BRVE listed on?

Braveheart Bio, Inc. Common Stock (BRVE) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time BRVE quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=BRVE`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Braveheart Bio, Inc. Common Stock (BRVE) insider trading](https://massive.com/quote/brve/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
